Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Safety, efficacy and immune effects of venetoclax 400 mg daily in patients with relapsed chronic lymphocytic leukemia (CLL).
Journal of Clinical Oncology (2016)
  • Matthew Steven Davids, Harvard University
  • Andrew Warwick Roberts, Royal Melbourne Hospital
  • John Francis Seymour, University of Melbourne
  • John F. Gerecitano, Memorial Sloan Kettering Cancer Center
  • Brad S. Kahl, University of Wisconsin-Madison
  • Thomas J. Kipps, University of California, San Diego
  • John M. Pagel, Cancer Institute
  • Soham D. Puvvada, University of Arizona
  • Lori A. Gressick
  • Ming Zhu
  • Martin Dunbar
  • Brenda Chyla, Gulf Coast Regional Blood Center
  • Maria E. Verdugo
  • Su Young Kim
  • William G. Wierda, University of Texas MD Anderson Cancer Center
Disciplines
Publication Date
May 20, 2016
Citation Information
Matthew Steven Davids, Andrew Warwick Roberts, John Francis Seymour, John F. Gerecitano, et al.. "Safety, efficacy and immune effects of venetoclax 400 mg daily in patients with relapsed chronic lymphocytic leukemia (CLL)." Journal of Clinical Oncology (2016)
Available at: http://works.bepress.com/john-pagel/9/